Intuitive Surgical, Inc. vs Thomson Reuters Corp — how do they compare? Intuitive Surgical, Inc. trades at $415.78 (market cap $146.44B), while Thomson Reuters Corp trades at $100.95 (market cap $43.21B). The key difference: Intuitive Surgical, Inc. is far larger — about 3.4× Thomson Reuters Corp's market cap, and Thomson Reuters Corp pays a 2.64% dividend while Intuitive Surgical, Inc. pays none. Which is the better fit depends on your goals — on Pluang, investors hold Intuitive Surgical, Inc. for 84 Days and Thomson Reuters Corp for 63 Days on average.
| ISRG | TRI | |
|---|---|---|
Market Cap | $146.44B | $43.21B |
Volume | 1,895,430 | 1,017,653 |
Sector | Health | Industrials |
52-Week High | $592.85 | $163.45 |
52-Week Low | $332.02 | $76.55 |
Typical Hold Time | 84 Days | 63 Days |
Enterprise Value | $141.22B | $45.82B |
Dividend Yield | — | 2.64% |
Signals from Pluang's Aura AI — not financial advice
Intuitive Surgical (ISRG) trades at $415.41, up 2.63% with strong technical momentum and bullish moving averages. The company demonstrates robust fundamentals with 2025 revenue of $10.06B and net income of $2.86B, maintaining impressive 28.45% net margins. Recent earnings beats and expansion into new markets like India and Japan support growth despite China headwinds. Technical indicators show the stock trading near pivot point resistance at $414 with support at $411.
ISRG presents a compelling growth story with dominant robotics positioning and expanding international footprint. The 17% selloff creates opportunity with 16% upside to consensus target of $480.78. Key risks include competitive pressures in robotic surgery and procedure growth normalization. Analyst consensus remains strongly bullish with 70% buy ratings, though valuation multiples remain elevated at P/E of 47.54.
Thomson Reuters (TRI) stock trades at $101.55, up 3.53% today, showing strong momentum amid positive technical signals and fundamental strength. The company demonstrates robust profitability with 75.7% gross margins and 21.22% net income margins, supported by 10% organic growth in core businesses. Recent developments include the successful divestment of its printing unit and the launch of proprietary AI technology, positioning TRI for continued growth in the legal and professional information markets.
With analyst consensus pointing to 31% upside to the $133.25 price target and strong institutional buying, TRI presents a compelling growth opportunity. However, investors should monitor execution risks around AI integration and potential cybersecurity vulnerabilities following recent incidents. The stock's current valuation at 26.16x P/E appears reasonable given the company's recurring revenue model and market leadership position.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
No sentiment data available yet.
Latest headlines on both assets
Intuitive Surgical develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed nearly 7,000 da Vinci systems in hospitals worldwide, with more than 4,000 installations in the United States and a growing number in emerging markets.
Read more on ISRG →Thomson Reuters is the result of the $17.6 billion megamerger of Canada's Thomson and the United Kingdom's Reuters Group in 2008 and the 2018 carve-out of its finance and risk business, Refinitiv, in which it holds a 45% stake. In 2019, the company agreed to exchange its 45% stake in Refinitiv for a 15% stake in LSE, which closed in early 2021. Since the divestiture, the company is more concentrated on selling its flagship legal data and software, Westlaw, and its tax accounting software, Onesource. Reuters sees roughly 80% of revenue and 70% of expenses attributed to the United States, while the remainder (largely through the global print and Reuters News segments) is distributed across Latin America, Europe, the Middle East, Africa, and Asia-Pacific.
Read more on TRI →